Eikon Therapeutics, Inc.

Filing Date

Feb 4, 2026

Transaction Date

Feb 4, 2026

Accession Number

0001193125-26-038136

Form Type

3

Footnotes

1. (F1)The Series A-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ("IPO"), all shares of Series A-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
2. (F2)The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person has the sole pecuniary interest in the securities.
3. (F3)The Series D Preferred Stock is convertible into Common Stock on a 1-for 7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series D Preferred Stock will be converted into shares of Common Stock of the Issuer.
4. (F4)The shares underlying the option will vest in equal monthly installments for four years after the vesting starting date, subject to the Reporting Person's continued service through each date.